149 related articles for article (PubMed ID: 38141814)
1. Are Manufacturing Patents to Blame for Biosimilar Market Launch Delays?
Williamson R; Munro T; Ascher D; Robertson A; Pregelj L
Value Health; 2024 Mar; 27(3):287-293. PubMed ID: 38141814
[TBL] [Abstract][Full Text] [Related]
2. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
Moorkens E; Vulto AG; Huys I
MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
[TBL] [Abstract][Full Text] [Related]
3. Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation.
Van de Wiele VL; Kesselheim AS; Sarpatwari A
Health Aff (Millwood); 2021 Aug; 40(8):1198-1205. PubMed ID: 34339242
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars in the United States: Emerging Issues in Litigation.
Wong AY; Rumore MM; Chan AW
BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
[TBL] [Abstract][Full Text] [Related]
5. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Dutta B; Huys I; Vulto AG; Simoens S
BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
[TBL] [Abstract][Full Text] [Related]
6. Cost to Medicare of Delayed Adalimumab Biosimilar Availability.
Lee CC; Najafzadeh M; Kesselheim AS; Sarpatwari A
Clin Pharmacol Ther; 2021 Oct; 110(4):1050-1056. PubMed ID: 34145566
[TBL] [Abstract][Full Text] [Related]
7. Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.
Horrow C; Gabriele SME; Tu SS; Sarpatwari A; Kesselheim AS
JAMA Intern Med; 2024 May; ():. PubMed ID: 38739386
[TBL] [Abstract][Full Text] [Related]
8. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
[TBL] [Abstract][Full Text] [Related]
9. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting.
Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I
BioDrugs; 2019 Jun; 33(3):285-297. PubMed ID: 30945207
[TBL] [Abstract][Full Text] [Related]
10. Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies.
Moorkens E; Jonker-Exler C; Huys I; Declerck P; Simoens S; Vulto AG
Front Pharmacol; 2016; 7():193. PubMed ID: 27445826
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars: impact of differences with Hatch-Waxman.
Kowalchyk K; Crowley-Weber C
Pharm Pat Anal; 2013 Jan; 2(1):29-37. PubMed ID: 24236968
[TBL] [Abstract][Full Text] [Related]
12. Explaining biosimilars and how reverse engineering plays a critical role in their development.
Bellinvia S; Edwards CJ
Expert Opin Drug Discov; 2020 Nov; 15(11):1283-1289. PubMed ID: 32717155
[TBL] [Abstract][Full Text] [Related]
13. The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyond.
Chang LC
J Food Drug Anal; 2019 Jul; 27(3):671-678. PubMed ID: 31324283
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland.
Carl DL; Laube Y; Serra-Burriel M; Naci H; Ludwig WD; Vokinger KN
JAMA Netw Open; 2022 Dec; 5(12):e2244670. PubMed ID: 36459139
[TBL] [Abstract][Full Text] [Related]
15. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting.
Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I
BioDrugs; 2019 Jun; 33(3):299-306. PubMed ID: 30945206
[TBL] [Abstract][Full Text] [Related]
16. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology.
Kalantar-Zadeh K
Am J Nephrol; 2017; 45(3):235-247. PubMed ID: 28142147
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.
Lee HJ; Han E; Kim H
Appl Health Econ Health Policy; 2020 Aug; 18(4):557-566. PubMed ID: 31930450
[TBL] [Abstract][Full Text] [Related]
18. A health economic guide to market access of biosimilars.
Simoens S; Vulto AG
Expert Opin Biol Ther; 2021 Jan; 21(1):9-17. PubMed ID: 33206021
[No Abstract] [Full Text] [Related]
19. Biological patent thickets and delayed access to biosimilars, an American problem.
Goode R; Chao B
J Law Biosci; 2022; 9(2):lsac022. PubMed ID: 36072417
[TBL] [Abstract][Full Text] [Related]
20. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
Declerck P; Danesi R; Petersel D; Jacobs I
Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]